Join Our Mailing List:
 
Follow Us:
Shop Contact Us
You have 0  Item in Cart | View Cart
310-841-2600
Featured Events
View All Events
Christiane Querfeld, M.D., Ph.D.
Research performed at: City of Hope Comprehensive Cancer Center
Specialty/Research Area: Cutaneous Lymphoma
Award Year: 2018
Career Summary:  Christiane Querfeld, M.D., Ph.D. is a board certified dermatologist and dermatopathologist who specializes in the diagnosis and treatment of cutaneous lymphoma.  She is the Director of the Cutaneous lymphoma Program and Assistant Professor at City of Hope National Medical Center.  Dr. Querfeld received her M.D. at the University of Cologne and a Ph.D. at the University of Heidelberg.  She then completed her internship at Johns Hopkins University, her dermatology training at University of Chicago and fellowships in dermatopathology and cutaneous lymphoma at Northwestern University.  In addition to her STOP CANCER Award, Dr. Querfeld is the recipient of the Northwestern Memorial Foundation Young Investigator Award (2005), the Cutaneous lymphoma Foundation Young Investigator Award (2006), Chicago Dermatological Society Research Award (2009), the Celgene Future Leader in hematology Award (2011), the Junior Investigator Research Development Award (2016), the City of Hope Pilot Project Award (2017), and the City of Hope Excellence Award (2017).

Year STOP CANCER Award was received:  2018 Research Career Development Award

Description of research performed:  Cutaneous T cell lymphoma (CTCL) is a disfiguring, incurable malignancy with a poor prognosis for those with advanced disease. Dr. Querfeld is focused on investigating the role played by the environment surrounding CTCL in the body.

Results of research:  Dr. Querfeld’s laboratory has produced preliminary data that have shown that T cells that normally attack tumors become exhausted in the CTCL environment. The group determined that immune checkpoint proteins (PD1, PD-L1, and ICOS) affect T cell function and the interaction with other cells known as dendritic cells and macrophages. Dr. Querfeld is using her results to conduct a promising clinical trial of a two-drug immunotherapeutic regimen. 

STOP CANCER is committed to funding the most promising and innovative scientists in their early research of all forms of cancer prevention, treatment, cures and subsequent clinical applications. STOP CANCER works primarily with local National Cancer Institute-designated Comprehensive Cancer Centers and other qualified institutions in the United States to carry out its mission.

Copyright © 2017 STOP CANCER. All Rights Reserved. | Privacy Policy